|
F. Raymond Salemme brings more than 30 years of broad biotechnology and entrepreneurial expertise to GNS. He holds the post of CEO of Linguagen Corp., the leading developer of all-natural additives that allow pharmaceutical, food and beverage companies to improve the taste or potency of their ingredients. After founding 3-Dimensional Pharmaceuticals (3DP) in 1993, Dr. Salemme ultimately grew the company to more than 200 employees and an IPO market capitalization of more than $330 million. He helped facilitate the NASDAQ-listed company’s sale to Johnson & Johnson in 2003. Prior to 3DP, Dr. Salemme held scientific and executive roles at Sterling Winthrop Pharmaceuticals, DuPont Merck Pharmaceuticals and Genex Corporation. He also served as a professor of biochemistry at the University of Arizona. Dr. Salemme is a member of the NIST Visiting Committee on Advanced Technology, and serves on multiple advisory boards, including those of the NIH National Center for Biotechnology Information and the Penn State University Nanotechnology Center. Dr. Salemme holds 21 patents in the areas of cheminformatics, computer-directed drug discovery, and high-throughput thermodynamic screening technology, and has published more than 80 scientific papers. He received a Ph.D. in chemistry from U.C. San Diego and B.A. in molecular biophysics from Yale University. | 